Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PCBP | ISIN: US10501L1061 | Ticker-Symbol:
NASDAQ
05.06.25 | 15:30
10,600 US-Dollar
0,00 % 0,000
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
BRAINSWAY LTD ADR Chart 1 Jahr
5-Tage-Chart
BRAINSWAY LTD ADR 5-Tage-Chart

Aktuelle News zur BRAINSWAY Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoBrainsWay invests $5M in Stella Mental Health to expand access to Deep TMS therapy1
BRAINSWAY Aktie jetzt für 0€ handeln
DoBrainsWay Invests $5 Mln In Stella To Expand Access To Advanced Neurostimulation Therapy2
MiBrainsWay invests $5 million in Stella Mental Health1
MiBrainsWay Announces $5 Million Minority-Stake Investment in Stella MSO, LLC1
MiBrainsway Ltd. - 6-K, Report of foreign issuer2
27.05.BrainsWay stock holds $16 target, Buy rating at H.C. Wainwright1
13.05.Brainsway Inc. Q1 Earnings Summary-
13.05.BrainsWay GAAP EPS of $0.02 in-line, revenue of $11.54M beats by $0.09M1
13.05.BrainsWay Reports First Quarter 2025 Financial Results and Operational Highlights136Achieved record quarterly sales of $11.5 million in Q1 2025, an increase of 27% compared to Q1 2024 Operating profit totaled $0.6 million and Adjusted EBITDA rose to $1.3 million, increasing by...
► Artikel lesen
13.05.Brainsway Ltd. - 6-K, Report of foreign issuer-
12.05.BrainsWay Q1 2025 Earnings Preview1
22.04.BrainsWay files to sell up to 3.6M American Depositary Shares for holders3
11.03.BrainsWay Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights208Achieved record quarterly sales of $11.4 million in Q4 2024, an increase of 27% compared with Q4 2023 Full year 2024 revenue increased nearly 30% YoY to $41 million Exceeded full year 2024 operating...
► Artikel lesen
11.03.BrainsWay GAAP EPS of $0.04 beats by $0.02, revenue of $11.41M beats by $0.52M2
11.03.Brainsway Ltd. - 6-K, Report of foreign issuer2
10.03.BrainsWay Q4 2024 Earnings Preview2
12.12.24BrainsWay Reports Positive Independent Pilot Data on Accelerated Deep TMS Treatment of Alcohol Use Disorder1
12.12.24Brainsway Ltd. - 6-K, Report of foreign issuer-
12.11.24BrainsWay Reports Third Quarter 2024 Financial Results and Operational Highlights183Robust 26% Year-over-Year Revenue Growth in Q3 2024 Raising Full-Year 2024 Revenue Guidance to $40-41 Million and Initiating Profitability Guidance Conference Call to be Held Today at 8:30 AM ET BURLINGTON...
► Artikel lesen
29.08.24BrainsWay Appoints Richard A. Bermudes, M.D. as Chief Medical Officer154BURLINGTON, Mass. and JERUSALEM, Aug. 29, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments...
► Artikel lesen
Weiter >>
21 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1